Introduction
Bone marrow/stem cell transplantation (BMT/SCT) remains an important curative therapy for hematologic malignancies, and its success is primarily a result of the generation of donor T cell-mediated graftversus-leukemia (GVL) effects. The complicating factor for BMT/SCT recipients is the risk of developing graft-versus-host disease (GVHD) within the gastrointestinal tract, liver, and skin. 1 GVHD requires the differentiation of donor T cells and is mediated by both the cytolytic pathways of donor T cells and proinflammatory cytokines. GVHD can be either acute (aGVHD) or chronic (cGVHD), both of which have a significant impact on patient morbidity and mortality, and, despite advances in immunosuppressive therapies, their incidence remains high. 2, 3 Therefore a major goal in BMT/SCT remains to prevent GVHD while maintaining GVL effects.
GVHD pathology is initiated by conditioning-induced damage/ pathogen-associated molecular patterns and inflammatory cytokine release, which promotes host antigen-presenting cell activation and alloantigen-specific donor T-cell differentiation. Although it has been widely recognized that CD4
1 T cell-derived interferon-g (IFNg)
is central to this process, 4 the role of IL-17 has been more recently established. 5 
IL-17 is expressed by both innate and adaptive immune cells including conventional T cells, mucosal-associated invariant T cells (MAIT), natural killer (NK), invariant NK T cells (iNKT), and
gd T cells, [6] [7] [8] [9] [10] [11] and is known to contribute to the pathogenesis of many autoimmune diseases as well as play a role in host defense from infection and malignancy.
9,12-14 IL-17-producing CD4 1 T cells (Th17)
have been extensively characterized in a variety of disease settings; however, IL-17-producing CD8 1 T cells (Tc17) have received comparatively little attention and as a result are relatively poorly understood. We have previously reported that the mobilization of stem cells in donors with granulocyte colony-stimulating factor (G-CSF) promotes Th17 and Tc17 differentiation and that donor IL-17A, which is predominantly derived from Tc17, drives sclerodermatous GVHD after allogeneic SCT (allo-SCT). 15 However, little is known about the nature of Tc17 that develop posttransplant, or their developmental requirements or functional capabilities. We used an IL-17 "fate mapping" reporter model to characterize Tc17 development, plasticity, and function in the context of GVHD and to investigate potential routes of therapeutic intervention. 16 Mice were housed in sterilized micro-isolator cages and received acidified autoclaved water (pH 2.5) after transplantation. All animal experiments were approved by and performed in accordance with the QIMR Berghofer Animal Ethics Committee.
Methods

Stem cell/bone marrow transplantation
Recipient mice received 900 (Balb/c), 1000 (bm1, B6), or 1100 (B6D2F1, CD11c.DOG.F1) cGy total-body irradiation ( 137 Cs source at 84.6cGy/min) split over 2 doses (d21). Grafts composed of either 10 3 10 6 G-CSF-treated splenocytes (B6D2F1, B6, CD11c.DOGF1) or 5 3 10 6 bone marrow 1 0.2 3 10 6 Biomag purified T cells (Bm1) were injected (d0). Recombinant human G-CSF was given subcutaneously to donors at 10 mg/dose per animal (4-6 days). 15 T-cell depletion (TCD) was performed by anti-CD4 (RL172.4), anti-CD8 (TIB211), and anti-Thy1.2 (HO-13-4) treatment, followed by rabbit complement. 17 Cell suspensions contained ,1% viable CD3 1 T cells.
Leukemic cells B6D2F1.BCR/ABL-NUP98/HOXA9 (GFP
) were generated as described. 18 Mice that developed clinical scores $6 and/or high leukemia burdens (white blood cell count .100 3 10 6 ) were sacrificed. In CD8 1 T-cell mixing transplants, mice received either 0. 1 T cells and 10 3 10 6 TCD bone marrow (Balb/c recipients). G-CSF-treated donor mice were given anti-CD8b-depleting mAbs (53.5.8) on d25 and d22. CD8
1 T cells were isolated from donor mice treated with G-CSF in parallel (B6D2F1 recipients). For in vivo depletion of inducible diphtheria toxin receptor (iDTR) expressing cells, diphtheria toxin from Corynebacterium diphtheriae was administered intraperitoneally (IP) at 250 ng per dose on d4, d5, and d6. In long-term experiments, mice were additionally treated with diphtheria toxin at 100 ng per dose on d10, d13, d17, and d20 posttransplant (Sigma-Aldrich, St. Louis, MO). Non-GVHD control groups were injected with TCD grafts. Mice were monitored daily and systemic GVHD assessed weekly using a cumulative scoring system. 19 Mice with GVHD scores $6 were culled and the date of death registered as the next day. For histologic analysis, tissue was fixed in paraformaldehyde and embedded in paraffin before tissue sectioning and hematoxylin and eosin staining.
Monoclonal antibodies
A list of antibodies used is provided in supplemental Table 1 . Rat anti-mouse IL-6R mAb (MR16-1, provided by Chugai Pharmaceutical Co, Japan) or Rat IgG (Sigma-Aldrich) was given IP at 500 mg per dose on d21 and d3 post-SCT as described. 20 Mouse anti-transforming growth factor-b (TGFb) mAb (1D11) and 
YFP
1 absolute numbers 7 days after syngeneic or allogeneic SCT (mean 6 SEM, n 5 6-10 pooled mice/ group from 2 independent experiments; **P , .01, ****P , .0001). (D) Representative FACS analyses and frequencies of CD8 1 T cells 7 days after allo-SCT costained with Annexin V and 7-AAD viability dye (mean 6 SEM, n 5 9-10 mice/group).
matched IgG isotype 13C4 (provided by Genzyme Corporation, Framingham, MA) was administered IP at 500 mg per dose on d0 and 100 mg per dose on d2, d4, and d6 posttransplant. Anti-IL-12/23p40 (C17.8) and matched-control IgG (Anti-AGP3 [cIg, 4D2]) were administered IP at 500 mg per dose on d22, d0, d2, d4, and d6 pre-/posttransplant (AMGEN Inc., Thousand Oaks, CA).
Cell preparation, culture, and cytokine analysis Cells were isolated by mechanical disruption and treated with lysis buffer to remove contaminating erythrocytes. For intracellular cytokine staining, cells were cultured with phorbol 12-myristate 13-acetate (5 mg/mL) and ionomycin (50 mg/mL) (Sigma-Aldrich) for 4 hours with Brefeldin A (BioLegend, San Diego, CA) included in the final 3 hours of incubation. Cells were surface-labeled and processed for intracellular staining, cytokines were assessed via cytofix/ cytoperm kit (BD Biosciences, Franklin Lakes, NJ), and nuclear staining performed via fixation and permeablization (eBioscience, San Diego, CA). All samples were acquired on BD LSR Fortessa (BD Biosciences) using BD FACSDiva (v7.0) and analyzed with FlowJo software (v9.7, Ashland, OR).
Gene expression analysis
Total RNA was extracted with the RNeasy Micro kit (QIAGEN, The Netherlands) from sort-purified (.95% purity) cells and gene expression determined using TaqMan GE assays (Applied Biosystems, Waltham, MA 
Statistical analysis
Survival curves were plotted using Kaplan-Meier estimates and compared by log-rank analysis. An unpaired 2-tailed Mann-Whitney U test was used to evaluate differences in cytokine and mRNA studies. Data are mean 6 standard error of the mean (SEM) and P , .05 is considered significant. Gene expression by microarray was assessed after Benjamini-Hochberg false discovery rate correction by unpaired Student t test (P , .05 cutoff) via GeneSpring GX v12.5 software, and then supervised hierarchical clustering performed. Seven-hundred two differentially expressed probes with .1.2-fold change were identified by unpaired Student t test (P , .05 cutoff) and this dataset was used in IPA analysis.
Results
Tc17 development after allo-SCT is an early and transient phenomenon
To track Tc17 induction and differentiation we used an IL-17A "fatemapping" reporter donor IL-17 Cre Rosa26 eYFP , which permanently induces YFP expression in IL-17A2producing cells regardless of ongoing IL-17A gene expression. 16 In time course experiments, CD8
1 YFP 1 Tc17 cells were rapidly induced in all lymphoid tissues spleen or (D) liver and assessed 1 to 3 weeks post-allo-SCT as indicated (mean 6 SEM, n 5 $5 mice/group; *P , .05, **P , .01, ***P , .001, ****P , .0001).
BLOOD, 24 SEPTEMBER 2015 x VOLUME 126, NUMBER 13 Tc17 DELETION TO SEPARATE GVHD AND GVL 1611 Figure 1C ). Given the relative enrichment of CD8 1 YFP 1 T cells in the liver, which is a known site of apoptotic clearance, 21 we examined CD8 1 T-cell apoptosis in both liver and spleen via Annexin V staining. We observed high levels of Annexin V binding in all CD8 1 T cells (;60%), which likely explains the overall decrease in organ cellularity normally observed between d7 and d21 in GVHD (data not shown). However, we did not detect any significant differences in apoptosis between CD8 1 YFP 1 and CD8 1 YFP neg counterparts in either spleen or liver T cells ( Figure 1D ). Because CD8
1 YFP 1 T cell numbers appear to preferentially decline between d7 and d14, these data suggest that differential levels of expansion may contribute to the observed shift in CD8 1 YFP 1 frequencies after d7. T cells express high levels of both Rorc and Tbet mRNA, the transcription factors associated with Th17/Tc17 and Th1/Tc1 differentiation, respectively ( Figure 3A) . In addition to increased expression of Rorc and Tbet in the CD8 population, including leukocyte adhesion/migration (Itga3, Integrin a3; Itgb4, Integrin b4), chemotactic factor/cytokines (Csf2, GM-CSF; Csf1, CSF-1), and chemokine/cytokine receptors (Ltb4r1, Leukotriene B4 receptor; Il1r2, IL-1R; Ccr6) ( Figure 3H ). The most highly upregulated gene in the CD8
1 YFP 1 population was Klrb1b, the murine homolog of CD161, whose expression in humans is a marker of IL-172 producing T cells. 22 In addition, we observed that the expression of a number of genes associated with cytolytic function were downregulated in CD8
1
YFP
1 cells, including those encoding the degranulation marker CD107a (Lamp1) and the CTL effector molecules FasL and Granzyme K. In agreement with intracellular cytokine staining, gene expression of the immunoregulatory cytokine IL-10 was also downregulated in the CD8 1 YFP 1 population, as was the IL-10 receptor (IL10ra) ( Figure 3H ), suggesting that not only are Tc17 poor immune regulators themselves, but they may also be less responsive to Tables 2 and 3 ).
BLOOD Tables  2 and 3 ). These data confirmed that these genes were significantly associated with inflammatory pathways and CTL activity and highlighted a number of potential upstream regulators including IL-10Ra, Eomes, FASL, and SOCS3.
Tc17 are a functionally distinct subset with reduced levels of CTL effector protein expression To confirm differences observed at the gene level, we assessed phenotypic markers associated with T-cell activation/memory, specialized T-cell subsets, chemokine/cytokine receptors, and CTL effector function after allo-SCT. Irrespective of YFP expression, the activation markers CD25, CD69, CD44, and costimulatory molecules CD27 and GITR were similarly expressed in all CD8
1 T cells 7 days after transplant ( Figure 4A) ; however, reduced frequencies of CD62L We next investigated the cytokine and antigen presentation requirements for iTc17 differentiation after allogeneic transplantation. Because both IL-6 and TGFb are known to drive Th17 polarization, we examined the effect of genetic ablation/antibody neutralization of these cytokines on iTc17 development. The absence of IL-6 had the most prominent effect, whereby mice that received IL-6 receptorblocking mAb after allo-SCT displayed significantly reduced CD8 1 YFP 1 frequencies and cell numbers in multiple tissues posttransplant ( Figure 5A ). Similarly, a significant reduction in CD8 1 YFP 1 numbers was also observed when IL-6 2/2 recipient mice were transplanted (data not shown), demonstrating that the source of IL-6 required for iTc17 induction is mainly host-derived. In contrast, administration of TGFb-neutralizing mAb had little effect on iTc17 development in this system, with only the spleen exhibiting a significant reduction in CD8 1 YFP 1 numbers after TGFb inhibition ( Figure 5B) . Neutralization of the shared p40 subunit of IL-12 and IL-23 resulted in a partial enhancement of iTc17 development, with increases in CD8 1 YFP 1 numbers in mesenteric and peripheral lymph nodes ( Figure 5C ). IFNg is the dominant cytokine downstream of IL-12 and its neutralization also resulted in a significant increase in CD8
1 YFP 1 frequencies in multiple tissues posttransplant ( Figure 5D ). CD8 1 YFP 1 development was robust in the B6→bm1 model of CD8-dependent GVHD induced by an isolated major histocompatibility complex class I mismatch ( Figure 5E ). This confirms that iTc17 can develop in a class I restricted manner in the absence of an alloreactive CD4 1 T-cell response, and therefore Figure 5F ). Given that iTc17 appear within the first week of BMT, before the reconstitution of donor DCs, 35 it would seem less likely that these cells initiate iTc17 development. These data demonstrate that primarily host-derived IL-6 and DCs drive the development of iTc17 cells after allo-SCT, and this process is inhibited by the presence of IFNg.
Targeted deletion of iTc17 protects against lethal GVHD
Given the proinflammatory phenotype exhibited by iTc17 (Figures 2  and 3 ), we hypothesized that by depleting these cells posttransplant, the severity of GVHD may be reduced. To test this, we used a second "deletable" fate-mapping system (IL-17
Cre Rosa26 iDTR ), in which the DT receptor is induced on IL-17-producing cells regardless of ongoing IL-17 gene expression. 36 By transplanting mice with CD8 Figure 6B-C) . In line with their proinflammatory phenotype, blinded histologic analysis demonstrated significantly reduced GVHD pathology in the colon tissue d7 posttransplant. Furthermore, we observed significant protection from lethal GVHD after iTc17 depletion in B6D2F1 recipients ( Figure 6D-E) , similar to that of Tc17-deficient grafts (Tc17 ko), where IL-17A 2/2 CD8 T cells were transplanted. In addition, we also demonstrated significant protection in an alternate major histocompatibility complex mismatch model of allo-SCT using Balb/c recipients ( Figure 6F ) and in a CD8 1 T cell-dependent model of GVHD ( Figure 6G ). These data confirm that iTc17 cells are a pathogenic population and represent a potential target for the prevention of GVHD.
iTc17 cells do not contribute to GVL effects
Because CD8 1 T cells are critical mediators of both GVHD and GVL posttransplant, and the quality of antitumor responses positively correlate with the incidence of GVHD, 37, 38 we assessed the contribution of iTc17 cells to GVL using a primary blast-crisis chronic myeloid leukemia (CML) model. Initial transplants were performed using B6. and d14, demonstrating the viability of iTc17 cells and their expansion after secondary transplantation; however, this expansion was not maintained during week 3, when tumor burdens were very high ( Figure 7C ). Importantly, in mice receiving CD8 1 YFP 1 T cells, leukemia was uncontrolled and both survival and tumor growth curves directly overlapped with that of the recipients receiving no donor T cells. In contrast, the majority of recipients of CD8 1 YFP neg donor T cells cleared leukemia within 3 weeks of transplantation, and antileukemic immunity was maintained long term ( Figure 7D-E) . Taken together, these data demonstrate that iTc17, which develop during GVHD, represent a unique, highly plastic, hyperinflammatory, noncytolytic CD8 1 T-cell effector population.
Discussion
Antitumor immunity and GVHD after allo-SCT are directly linked to donor T-cell differentiation. Although the role of T cell-derived IL-17 in GVHD is increasingly recognized, the focus has been predominantly on IL-17 production by CD4 1 T cells, whereas donor CD8 1 T-cell polarization in this context has been largely unappreciated. We have previously shown that in a murine model of allo-SCT, G-CSF mobilization promotes donor Th17/Tc17 differentiation and that IL-17A-deficient allografts protect recipients from CD8 1 T cellmediated sclerodermatous GVHD. 15 Recent studies in other disease 12, 32, 34, [39] [40] [41] ; however, plasticity studies of Tc17 have been limited to the use of in vitro polarized CD8 1 T cells. To circumvent this limitation, we used a murine IL-17A "fate-mapping" reporter model to characterize an inflammatory Tc17 lineage that develops during GVHD, and to our knowledge, we are the first to do so. We found that iTc17 development is both an early and transient phenomenon after allo-SCT dependent on host IL-6 and DCs, which is regulated by the presence of IL-12 and IFNg. The iTc17 subset displays considerable lineage promiscuity in transcriptional profile and cytokine production and targeted depletion of iTc17 cells early after transplant was protective in lethal models of acute GVHD. In contrast, iTc17 are significantly impaired in cytolytic and GVL activity and provide little or no direct antitumor immunity in vivo. iTc17 numbers declined dramatically in weeks 2 to 3 after transplant, although there was some evidence for their persistence in the liver. This Tc17 contraction is concordant with a human study in which CD161 was used as a surrogate marker of IL-17-producing T cells, 42 whereby a decline in CD8
1
CD161
1 T-cell frequencies in peripheral blood was observed over time after allo-SCT. Although previous attempts have been made to address the persistence of Tc17 cells in vivo, the significant level of plasticity observed in this population has hampered these questions. There are some data to suggest that in vitro, polarized Tc17 may be more persistent after adoptive transfer than Tc1-polarized CD8 1 T cells 41, 43 ; however, this was not the case in our in vivo murine system, where we observed a preferential decline in CD8
1
YFP
1 frequencies over time after transplant.
iTc17 plasticity was particularly striking early after transplant, whereby the majority of CD8
1
YFP
1 T cells had already downregulated IL-17 production as early as d7, highlighting the importance of a fate-mapping model to monitor this population. In addition, iTc17 also displayed considerable heterogeneity in cytokine expression. Notably, coexpression of both IL-17A and IFNg was observed early posttransplant, which appears to be a general feature of Tc17 cells. 15, 32, 34 This dual expression has been attributed to epigenetic suppression of the regulatory protein SOCS3, 32 whose absence in donor T cells we have shown to also result in polyfunctional T-cell responses and exacerbated GVHD. 44 In this study, we found that Socs3 gene expression was downregulated in CD8 Table 3 ). These data suggest that differential expression of Socs3 may also drive the hyperproinflammatory T-cell phenotype observed in iTc17. Multiple studies have looked at the mechanisms behind in vitro Tc17 plasticity, finding that IL-12 signaling via Stat4 is required for IFNg induction in both CD4 1 and CD8 1 populations during inflammation. 40, 45 This is also likely to be the case in the context of allo-SCT, because IL-12 is upregulated early posttransplant and is a well-described mediator of aGVHD. 46 Our comprehensive characterization of the CD8 pooled from 2 independent experiments (3-10 mice/group total 6 SEM; *P , .05, **P , .01, ***P , .001).
appears to be driven by dual expression of the transcription factors Tbet and RORgt, previously associated with an inflammatory profile likely to be protective during host-pathogen interactions in innate lymphoid cells and CD4 1 T cells. 47 However, the Tbet 1 RORgt 1 T-cell differentiation pathway may carry an increased risk of autoimmune disease pathologies, [47] [48] [49] which share many of the clinical and histologic features of GVHD. Similarly, expression of the transcription factor Eomes is negatively correlated with IL-17 expression 8,50,51 and has been reported to be necessary for full CTL effector function and is therefore likely to explain the poor cytotoxicity observed in the iTc17 population. 52 Because these iTc17 are difficult to identify after BMT based on surface marker and cytokine profiles (given their promiscuity), it may be that transcription factor expression instead represents a more useful approach to their identification. Given that these cells are in fact highly functional with regard to proinflammatory cytokine function, we propose that the iTc17 population represents a unique population of nonclassical effector CD8
1 T cells whose primary function is to contribute to inflammation and recruitment of both lymphoid and myeloid effector cells, resulting in GVHD pathology. In agreement with this, we observed significantly elevated Csf1 gene expression by CD8
T cells, which we have recently demonstrated in IL-17-dependent models of lung and sclerodermatous GVHD is a critical factor driving macrophage tissue infiltration and pathology. 53 The signaling pathways that contribute to type-17 differentiation are relatively well characterized, with IL-6, TGF-b, IL-21, and IL-23 promoting IL-17A production and both IFNg and IL-12 acting as regulators. 39 We have previously demonstrated that type-17 differentiation in G-CSF-mobilized donor T cells is highly IL-21-dependent, 15 and we now show that IL-6R signaling is also required for iTc17 differentiation, coinciding with the presence of elevated IL-6 levels in plasma early posttransplant. 20 These data are in line with previously published observations that IL-6R blockade significantly protects from lethal GVHD in murine models of GVHD. 20, 54 Furthermore, we have recently demonstrated in phase 1/2 clinical trials that IL-6R inhibition after allo-SCT is a promising therapeutic approach for GVHD intervention in humans. 55 In contrast, TGFb and IL-12/IL-23p40 were minor contributors to iTc17 development in our systems, with little to no effect observed on iTc17 differentiation when neutralized in vivo. IFNg neutralization significantly enhanced type-17 differentiation, consistent with the known crossregulation of lineage differentiation by IFNg and IL-17A. Importantly, iTc17 cells continue to produce high levels of IFNg in the absence of IL-17 production; thus, without a fate reporter, iTc17 are indistinguishable from Tc1 cells based on IFNg and IL-17 expression, and this likely contributes to our early observations regarding the disappearance of CD8
1 IL-17 1 T cells after transplantation.
Because GVHD arises as a complication to therapy designed to provide GVL effects, the identification of factors that contribute to GVHD but not GVL is highly desirable. The proinflammatory BLOOD, 24 SEPTEMBER 2015 x VOLUME 126, NUMBER 13 Tc17 DELETION TO SEPARATE GVHD AND GVL 1617
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From phenotype and impaired CTL effector function observed in iTc17 posttransplant suggested that this population may represent a suitable target for therapeutic intervention after allo-SCT. There are conflicting reports in the literature regarding the potential for cytolytic activity in Tc17 in vivo, particularly with regard to Tc1-shifted cells derived from the Tc17 subset. Reports of Tc17 CTL function range from enhanced in some studies 34, 40, 43 to diminished in others. 41, 56 In addition, other studies have suggested that Tc17 contribute to host protection via inflammatory mediators (such as IFNg) as opposed to cytotoxic mechanisms. 12, 57 Our studies demonstrate that CD8
1 YFP 1 iTc17 cells cannot eradicate leukemia in vivo, which is concordant with their uniformly poor expression of factors including Eomes (previously linked with poor antitumor immunity) 58 and the cytolytic effector molecule Granzyme B. 59 This study provides new insights into donor T-cell polarization after allo-SCT, demonstrating that iTc17 differentiation is an early and highly plastic differentiation program culminating in a poorly cytolytic, hyperinflammatory donor T cell. Intervention to prevent this differentiation program, putatively via either IL-6 or RORgt 
